HaTay Pharmaceutical JSC

HaTay Pharmaceutical JSC OCF/Debt

The Operating Cash Flow to Debt Ratio of HaTay Pharmaceutical JSC (DHT.VN) as of Nov 3, 2026 is 5.95 %. In the previous year, Operating Cash Flow to Debt Ratio was 53.76 % — a change of -88.94% (lower).

OCF/Debt

5.95 %

YoY

-88.94%

Last updated:

Operating Cash Flow to Debt Ratio of HaTay Pharmaceutical JSC is 2024 5.95 % . Operating Cash Flow to Debt Ratio of HaTay Pharmaceutical JSC was 2023 53.76 % . It decreases by -88.94% lower compared to the previous year.

The HaTay Pharmaceutical JSC OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2017
1.30 VND
Jan 1, 2018
46.92 VND
Jan 1, 2019
66.08 VND
Jan 1, 2020
46.38 VND
Jan 1, 2021
-8.05 VND
Jan 1, 2022
-11.72 VND
Jan 1, 2023
53.76 VND
Jan 1, 2024
5.95 VND
The HaTay Pharmaceutical JSC OCF/Debt history
YEAROCF/DebtYoY
5.95 %-88.94%
53.76 %-558.80%
-11.72 %+45.61%
-8.05 %-117.35%
46.38 %-29.82%
66.08 %+40.83%
46.92 %+3,503.80%
1.30 %-95.16%
26.91 %-364.04%
-10.19 %-336.66%
4.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HaTay Pharmaceutical JSC Stock analysis

What does HaTay Pharmaceutical JSC do? Ha Tay Pharmaceutical JSC generates revenue through the manufacturing, import, and export of pharmaceuticals, cosmetics, and medical equipment. The company sells its products via wholesale and retail channels, targeting healthcare providers, pharmacies, and consumers. It also engages in the production and trading of cosmetic products, supplemental food, and laboratory chemicals, alongside medical equipment and supplies. The firm completed the acquisition of a 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company in 2013, expanding its market presence in pharmaceuticals and medical equipment. The company operates in the pharmaceutical sector, serving healthcare institutions, retail pharmacies, and end consumers. Its revenue streams include the sale of drugs, cosmetics, medical equipment, and related supplies. Additional income comes from supermarket operations, real estate leasing, and vocational training services, though these are secondary to its core pharmaceutical business. Ha Tay Pharmaceutical JSC's primary customers are healthcare providers, pharmacies, and consumers purchasing pharmaceuticals, cosmetics, and medical equipment. The firm's product portfolio spans drugs, vaccines, cosmetic products, supplemental food, and laboratory chemicals, with a focus on manufacturing and trading. The acquisition of the 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company has strengthened its position in the medical equipment market. HaTay Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HaTay Pharmaceutical JSC stock

Operating Cash Flow to Debt Ratio of HaTay Pharmaceutical JSC is 5.95 % in 2024.

Operating Cash Flow to Debt Ratio of HaTay Pharmaceutical JSC changed from 53.76 % to 5.95 %, representing a -88.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio HaTay Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's HaTay Pharmaceutical JSC with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — HaTay Pharmaceutical JSC

All Key Metrics — HaTay Pharmaceutical JSC